|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4545 | (2006.01) |
| A61K 31/4545 | (2013.01) | ||
| A61P 3/04 | (2006.01) | ||
| A61P 3/04 | (2018.01) | ||
| A61P 3/10 | (2006.01) | ||
| A61P 3/10 | (2018.01) | ||
| A61K 9/20 | (2006.01) | ||
| A61K 9/2054 | (2013.01) | ||
| A61K 9/2059 | (2013.01) | ||
| A61K 9/2086 | (2013.01) |
| (11) | Number of the document | 4125896 |
| (13) | Kind of document | T |
| (96) | European patent application number | 21714685.1 |
| Date of filing the European patent application | 2021-03-24 | |
| (97) | Date of publication of the European application | 2023-02-08 |
| (45) | Date of publication and mention of the grant of the patent | 2025-05-07 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/IB2021/052430 |
| Date | 2021-03-24 |
| (87) | Number | WO 2021/191812 |
| Date | 2021-09-30 |
| (30) | Number | Date | Country code |
| 202063000787 P | 2020-03-27 | US | |
| 202063126113 P | 2020-12-16 | US | |
| 202163135870 P | 2021-01-11 | US |
| (72) |
LEE, Kai Teck , GB
MANTHENA, Sweta , US
SAXENA, Aditi Rao , US
|
| (73) |
Pfizer Inc. ,
66 Hudson Boulevard East, New York, NY 10001-2192,
US
|
| (54) | TREATMENT OF TYPE 2 DIABETES WITH 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-YL} PIPERIDIN-1-YL)METHYL]-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID OR A PHARMACEUTICALLY SALT THEREOF |
| TREATMENT OF TYPE 2 DIABETES WITH 2-[(4-{6-[(4-CYANO-2-FLUOROBENZYL)OXY]PYRIDIN-2-YL} PIPERIDIN-1-YL)METHYL]-1-[(2S)-OXETAN-2-YLMETHYL]-1H-BENZIMIDAZOLE-6-CARBOXYLIC ACID OR A PHARMACEUTICALLY SALT THEREOF |